City briefs: Surgical Innovations Group
Leeds-based MedTech business, Surgical Innovations Group, has appointed Jonathan Glenn as senior independent non-executive director and chairman-designate with immediate effect.
Glenn is an experienced board director and chairman.
He is currently non-executive chairman of Tissue Regenix plc, and was formerly group CEO of Consort Medical Plc from 2007 to 2020, where he oversaw the £230m acquisition of a European contract development and manufacturing organisation. J
He led the business as CEO until its acquisition for £505m in 2020. He is a member of the Institute of Chartered Accountants in England and Wales.
Glenn joins the board in anticipation of the upcoming retirement of Professor Mike McMahon, the founder of the company, who retires from the board at the Annual General Meeting of the business which is expected to take place on 27 June 2023.
Glenn will succeed Nigel Rogers as chairman upon announcement of the interim results expected in September 2023.
Rogers has indicated his intention to remain on the board until an additional independent non-executive director has been appointed.
Rogers said: “It has been my great pleasure to lead the board since my appointment in 2015, and especially to work alongside Prof Mike McMahon.
“As part of our planned succession arrangements, we are now pleased to have Jonathan joining us, and look forward to working with him to complete the transition in board composition for the next stage in the company’s evolution.”
